These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 15212037

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [The industrialisation of therapeutic agents: a story of practices between science, technology, medicine and the law].
    Gaudillière JP.
    Gesnerus; 2007; 64(1-2):93-108. PubMed ID: 17982961
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT, Hagie F, Keen CL, Gershwin ME.
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [Abstract] [Full Text] [Related]

  • 5. The learned intermediary doctrine: past, present and future.
    Alsobrook HB.
    Leg Med; 1994 Jan; ():269-80. PubMed ID: 7830482
    [No Abstract] [Full Text] [Related]

  • 6. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH.
    Food Drug Law J; 2007 Jan; 62(2):399-422. PubMed ID: 17632969
    [No Abstract] [Full Text] [Related]

  • 7. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J.
    New Yorker; 2006 Dec 18; ():40-7. PubMed ID: 17176539
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS.
    N Engl J Med; 2010 Nov 04; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL, Quinn VM, Brophy EA.
    Food Drug Law J; 2006 Nov 04; 61(4):585-622. PubMed ID: 17180765
    [No Abstract] [Full Text] [Related]

  • 15. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME.
    Food Drug Law J; 2008 Nov 04; 63(1):275-320. PubMed ID: 18561462
    [No Abstract] [Full Text] [Related]

  • 16. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R, Yolkut D, Connolly DR.
    Tort Trial Insur Pract Law J; 2005 Nov 04; 40(3):997-1017. PubMed ID: 16100814
    [Abstract] [Full Text] [Related]

  • 17. Drug product liability and health care delivery systems.
    Sage WM.
    Stanford Law Rev; 1988 Apr 04; 40(4):989-1026. PubMed ID: 10318110
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL.
    Food Drug Law J; 2005 Apr 04; 60(2):261-338. PubMed ID: 16094773
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.